Lenoir, NC February 17, 2017 – Exela Pharma Sciences today announced that it received FDA approval for Ganciclovir Injection in 0.8% sodium chloride solution. Ganciclovir Injection is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (AIDS) and for the prevention of CMV disease in adult transplant recipients at risk for CMV disease. Ganciclovir carries a boxed warning. Please see safety information below and additional important safety information in the full prescribing information by clicking here. Exela’s Ganciclovir Injection is the first ganciclovir product available in a ready to use formulation. 
Read More

Lenoir, NC March 9, 2017 – Exela Pharma Sciences today announced that it received FDA approval for NIPRIDE RTU (sodium nitroprusside) in 0.9% sodium chloride injection, the company’s second FDA approval this year. NIPRIDE RTU (sodium nitroprusside) is indicated for the immediate reduction of blood pressure of adult and pediatric patients. NIPRIDE RTU is also indicated for producing controlled hypotension to reduce bleeding during surgery. NIPRIDE RTU is also indicated for the treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure,  peripheral vascular resistance and mean arterial blood pressure. NIPRIDE RTU carries a boxed
Read More